Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services worldwide. Its flagship product, Dtect genetic screening tests which inspects DNA for markers associated with genetic variations that influence various biological processes. The company also offers genome sequencing services for humans, animals, plants, and microbes and other living organisms; transcriptome sequencing; and metagenomics and metatranscriptomics. In addition, it provides genome analysis services, including bioinformatics, trait analysis, and trio sequencing; genetic screening services, such as Dtect and Origene genetic screening test; and CAR T-cell immunotherapy treatment for different types of cancer. Further, it is involved in dealing in capital markets and derivative instruments; acting as general merchants; business relating to life sciences/cell lab and by products; and distribution of healthcare products, beauty products, and precision medicine. Additionally, the company provides system developments and information technology comprising software and hardware, as well as other human health services and general medical services. The company has research and development collaborations with Universiti Sains Malaysia; De Cell Berhad; Twsitcode Technologies Sdn Bhd; Kumpulan Medic Iman Sdn Bhd; Innoquest Pathology Sdn Bhd; and Kumpulan Perubatan Penawar Sdn Bhd and Hospotal Penawar Sdn Bhd. Malaysian Genomics Resource Centre Berhad was incorporated in 2004 and is headquartered in Petaling Jaya, Malaysia.
Metrics to compare | MGRC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMGRCPeersSector | |
---|---|---|---|---|
P/E Ratio | −7.8x | −3.5x | −0.5x | |
PEG Ratio | −0.10 | 0.00 | 0.00 | |
Price/Book | 1.6x | 1.1x | 2.6x | |
Price / LTM Sales | 5.4x | 1.8x | 3.2x | |
Upside (Analyst Target) | - | 92.1% | 43.8% | |
Fair Value Upside | Unlock | 27.4% | 8.1% | Unlock |